Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich'sataxia (FA) patients
Placebo-controlled Phase 1 trials in FA patients remain on track for topline data in Q2 2021